ImmunoGen Shares Takes Flight On Ovarian Cancer Survival Data


Funding Overview

ImmunoGen (NASDAQ:IMGN) – an underneath the radar, Waltham, Massachusetts based mostly biotech based in 1981 despatched its shareholders into raptures yesterday after publishing new information from its Section 3 MIRASOL examine of its drug ELAHERE, in sufferers with FRα-Constructive, Platinum-Resistant Ovarian Most cancers (“PROC”).

Elahere development strategy

ELAHERE improvement technique (ImmunoGen presentation)

Elahere current guidelines and development program

ImmunoGen affected person alternative forecast for ELAHERE (ImmunoGen presentation)

Back To Top